Madrigal Pharmaceuticals MDGL shares soared 10.9% on Wednesday. The uptrend was observed after the U.S. Patent and Trademark ...

Madrigal Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 73 to 87.

Madrigal Pharmaceuticals shares rose after the biopharmaceutical company received a U.S. patent for its Rezdiffra treatment. Shares were up 11% at $345.24 Wednesday. The stock has been up 12.8% this ...

Madrigal Pharmaceuticals Inc. Madrigal Pharmaceuticals Inc MDGL. Stock XNAS Rating as of Jul 17, 2025. Download PDF. More Actions Summary; Chart; News; Price vs Fair Value; Sustainability; ...

The extended patent protection strengthens Madrigal’s market position by preventing generic competition for over two decades, ...

Madrigal Pharmaceuticals' (NASDAQ: MDGL) shares are down by 27% over the past year, while the S&P 500 is up by 26%. However, this poor performance hardly reflects the progress the biotech has made.

Madrigal Pharmaceuticals, Inc. stock has enjoyed peaks and troughs as it has pursued its path to the approval of NASH drug Rezdiffra. The company's stock was buoyant yesterday, enjoying a 15% gain ...

CONSHOHOCKEN, Pa., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic ...

Madrigal's share price rocketed >350% in December last year after positive data from a Phase 3 study of lead drug Resmetirom in NASH. Read more about MDGL here.

Madrigal Pharmaceuticals shares jumped as much as 23% on Friday after its oral drug became the first approved treatment for a fatty liver disease known as non-alcoholic steatohepatitis (NASH).

Patients with MASH/NASH treated with Rezdiffra experienced clinically meaningful and statistically significant improvements in emotional well-being and health distress Study results underscore the ...

Earlier this year, Madrigal Pharmaceuticals (NASDAQ: MDGL) launched its first product, Rezdiffra. It wasn't just an important breakthrough for the mid-cap biotech; Rezdiffra became the first ...